Headache News and Research

Latest Headache News and Research

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.

4 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Eli Lilly and Company announced today that Axiron® (testosterone) topical solution is available in pharmacies throughout the United States. Axiron is a prescription medicine used to treat adult males that have low or no testosterone. Safety and efficacy of Axiron in males younger than 18 years of age have not been established.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

Consumption of popular pain reliever during pregnancy may put children at increased risk for asthma

A new study published in the journal Clinical & Experimental Allergy reveals that children whose mothers used the popular pain reliever paracetamol during pregnancy were at an increased risk of wheezing when compared to non-users.

28 Mar 2011

Panax ginseng, saffron and yohimbine can boost human sexual function

Looking to spice up your sex life? Try adding ginseng and saffron to your diet. Both are proven performance boosters, according to a new scientific review of natural aphrodisiacs conducted by University of Guelph researchers.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

Pregnant women can benefit from low-to-moderate intensity weight-training program

Despite decades of doctors' reluctance to recommend weight training to pregnant women, a new University of Georgia study has found that a supervised, low-to-moderate intensity program is safe and beneficial.

28 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients

Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.

25 Mar 2011

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.

25 Mar 2011

Study finds risk of heart attack among patients with TIA

Patients who have suffered a "mini stroke" are at twice the risk of heart attack than the general population, according to research reported in Stroke: Journal of the American Heart Association.

25 Mar 2011

Merck & Co receives FDA approval for Zostavax vaccine to treat shingles

The Food and Drug Administration today approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.

25 Mar 2011

Mosquitoes carry risk of Murray Valley encephalitis warn Victorian health authorities

After detecting some new cases of Murray Valley encephalitis in chickens, health authorities have warned Victorians to protect themselves from mosquito bites. Victoria's chief health officer, Dr John Carnie warned that the deadly disease had been detected in "sentinel" chickens at Cobram, Rutherglen, Toolamba and Bendigo. “These latest detections follow positive results in chickens in similar areas a month ago, including Barmah and Kerang… Evidence of the virus is again present in these areas,” Dr Carnie said.

24 Mar 2011

Aradigm fourth quarter revenue is $144,000 for 2010

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010.

24 Mar 2011

Headache News and Research

Latest Headache News and Research

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Positive results from Vertex VX-770 Phase 3 trial against CF

Consumption of popular pain reliever during pregnancy may put children at increased risk for asthma

Panax ginseng, saffron and yohimbine can boost human sexual function

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Pregnant women can benefit from low-to-moderate intensity weight-training program

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Study finds risk of heart attack among patients with TIA

Merck & Co receives FDA approval for Zostavax vaccine to treat shingles

Mosquitoes carry risk of Murray Valley encephalitis warn Victorian health authorities

Aradigm fourth quarter revenue is $144,000 for 2010

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Headache News and Research

Latest Headache News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in